Medtronic (NYSE:MDT) touted the launch of its AdaptResponse trial, the largest study of its kind evaluating the company’s AdaptivCRT algorithm for personalizing cardiac resynchronization therapy in treatment of heart failure.

The trial admitted its 1st of about 3,000 patients expected to participate at 200 centers worldwide, looking for worsening symptoms of heart failure and incidence of atrial fibrillation as well as quality of life and cost-effectiveness.

AdaptivCRT programming, available in pacemakers and defibrillators, detects and analyzes patients’ heart rhythms on a constant basis to automatically adjust and personalize therapy parameters. Medtronic has said that the algorithm helps improve patients’ response to therapy and reduces the risk of developing atrial fibrillation.

Patients in the new AdaptResponse will all receive AdaptivCRT-capable implants but will be randomized to treatment with the software switched on or off. Early follow-up will occur 3 months after the procedure and then every 6 months until the trial closes, according to a Medtronic press release.

The medtech titan has notched some important recent wins for its AdaptivCRT software, including this week’s receipt of FDA approval for the Viva CRT-P pacemaker and the approval for the Viva Quad XT and Viva Quad S defibrillators earlier this month.